Internal Medicine, Medical Oncology · Springfield, MO
NPI
1396764551
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3850 S National Ave, Suite 600
Springfield, MO, 65807
Phone (417) 882-4880
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
97,395 services
Medicare patients, 2024
539
Average age 74
Drug cost, 2024
$7.4M
1,971 prescriptions
Company payments, 2025
$1,581
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jiantao Ding was code J0185 (injection, aprepitant, 1 mg), 6,760 times for 13 patients. In total Jiantao Ding billed 97,395 services in 122 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 6,760 | 13 | $1.35 | $9,134 |
| J0897 Injection, denosumab, 1 mg | Office | 3,060 | 17 | $20.53 | $63K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,936 | 30 | $0.09 | $175 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,300 | 12 | $15.83 | $21K |
| 85025 Blood Count | Office | 1,045 | 323 | $7.60 | $7,938 |
| 36415 Venipuncture Blood Collection | Office | 768 | 280 | $8.64 | $6,636 |
| 99214 Office E&M - Established | Office | 678 | 261 | $86.00 | $58K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 650 | 20 | $0.69 | $447 |
| 80053 Clinical Chemistry | Office | 424 | 156 | $10.35 | $4,388 |
| 99213 Office E&M - Established | Office | 336 | 192 | $59.29 | $20K |
| 96413 Chemotherapy Administration | Office | 208 | 43 | $83.96 | $17K |
| 96372 Injection Administration | Office | 207 | 52 | $9.47 | $1,961 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 206 | 25 | $71.60 | $15K |
| 96375 Injection Administration | Office | 195 | 42 | $10.34 | $2,017 |
| 96367 Intravenous Infusion, Hydration | Office | 154 | 30 | $18.31 | $2,819 |
By year: 2022 $1.6M for 86,744 services; 2023 $1.7M for 83,785 services; 2024 $2.2M for 97,395 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,045 | 323 | $7.60 | $7,938 |
| 36415 Venipuncture Blood Collection | 768 | 280 | $8.64 | $6,636 |
| 80053 Clinical Chemistry | 424 | 156 | $10.35 | $4,388 |
Medicare prescription drug claims, 2024
In 2024, the drug Jiantao Ding prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 94 prescriptions and refills. In total Jiantao Ding wrote 1,971 Medicare prescriptions that cost $7.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 94 | 94 | 33 | $1,992 |
| Hydroxyurea Generic | 89 | 153 | 19 | $2,588 |
| Alprazolam Generic | 82 | 84 | 19 | $326 |
| Letrozole Generic | 81 | 140 | 19 | $1,433 |
| Oxycodone Hcl Generic | 75 | 75 | 38 | $1,258 |
| Imbruvica Ibrutinib | 67 | 67 | Under 11 | $1.1M |
| Ondansetron Hcl Generic | 59 | 67 | 24 | $2,599 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 58 | 58 | 19 | $1,218 |
| Levothyroxine Sodium Generic | 56 | 94 | 14 | $779 |
| Anastrozole Generic | 51 | 122 | 14 | $718 |
| Jakafi Ruxolitinib Phosphate | 47 | 47 | Under 11 | $794K |
| Eliquis Apixaban | 43 | 59 | Under 11 | $33K |
| Potassium Chloride Generic | 42 | 58 | 18 | $388 |
| Revlimid Lenalidomide | 40 | 40 | Under 11 | $762K |
| Brukinsa Zanubrutinib | 40 | 40 | Under 11 | $554K |
Brand drugs: - claims; generic drugs: 1,386 claims; opioid claims: 296.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jiantao Ding $1,581 ($1,581 in general payments such as food, travel and fees) from 23 companies. The largest payer was Janssen Biotech, Inc. with $338.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 5 | $338 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $207 |
| Stemline Therapeutics Inc. | 2 | $123 |
| Incyte Corporation INCY | 1 | $122 |
| Pfizer Inc. PFE | 12 | $121 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $94.29 |
| Gilead Sciences, Inc. GILD | 4 | $82.12 |
| Celgene Corporation BMY | 4 | $68.13 |
| Abbvie Inc. ABBV | 2 | $64.19 |
| Array Biopharma Inc PFE | 5 | $41.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.